Aurinia Pharmaceuticals

(NASDAQ) AUPH

Current Price$14.19

Market Cap$1.87B

Since IPO (2012)+591%

5 Year+1%

1 Year+88%

1 Month-3%

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

$1.87B

Revenue (TTM)

$283.05M

Net Income (TTM)

$287.20M

EPS (TTM)

$2.08

P/E Ratio

25.25

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$14.19

Volume

35,412

Open

$14.32

Price

$14.19

Volume

35,412

Open

$14.32

Previous Close

$14.17

Daily Range

$14.05 - $14.51

52-Week Range

$6.83 - $16.54

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$14.19

Volume

35,412

Open

$14.32

Previous Close

$14.17

Daily Range

$14.05 - $14.51

52-Week Range

$6.83 - $16.54

Estimated Earnings Date

N/A

AUPH News

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Jonathan PoncianoDec 2, 2025

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Peter S. Greenleaf, MBA

Website

www.auriniapharma.com

AUPH Financials

Key Financial Metrics (TTM)

Gross Margin

TBD

Operating Margin

TBD

Net Income Margin

TBD

Return on Equity

60%

Return on Capital

TBD

Return on Assets

TBD

Earnings Yield

3.96%

Dividend Yield

0.00%

Payout Ratio

TBD

Stock Overview

Market Cap

$1.87B

Enterprise Value

TBD

Shares Outstanding

131.84M

Float %

TBD

Volume

35.41K

Short Interest

0.00%

Avg. Volume

1.06M

FCF Yield

TBD

Financials (TTM)

Gross Profit

$250.39M

Operating Income

$104.91M

EBITDA

$127.76M

Operating Cash Flow

$135.66M

Capital Expenditure

$252.00K

Free Cash Flow

$135.41M

Cash & ST Invst.

$398.00M

Total Debt

$74.81M

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$77.11

+1.3%

Gross Profit

$68.31

+1.3%

Gross Margin

88.59%

+1.0%

Market Cap

$1.87B

N/A

Market Cap/Employee

$16.43

N/A

Employees

128

N/A

Net Income

$210.79

+147.5%

EBITDA

$33.03

+2.4%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$80.21

+1.0%

Accounts Receivable

$41.45

+1.1%

Inventory

$45.69

+1.2%

Long Term Debt

$57.22

+0.9%

Short Term Debt

$17.59

+1.2%

Return on Assets

43.47%

+41.5%

Return on Invested Capital

-20.76%

+0.8%

Free Cash Flow

$44.50

+1.5%

Operating Cash Flow

$44.57

+1.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$5.75-2.62%

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$30.29+0.66%

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$33.53+3.82%

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$28.62+0.27%

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$39.66+8.93%

BHVNBiohaven Ltd.

BHVNBiohaven Ltd.$11.55+0.26%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$3.66+1.42%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$7.08-0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$49.68+0.00%

TSLSDirexion Shares ETF Trust - Direxion Daily Tsla Bear 1x Shares

TSLSDirexion Shares ETF Trust - Direxion Daily Tsla Bear 1x Shares$5.65+0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$70.63-0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.61-0.01%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$89.52-0.01%

VGVenture Global

VGVenture Global$11.03+0.14%

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Financials at a Glance

AUPH News

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Aurinia (AUPH) Q2 Revenue Jumps 22%

Why Aurinia Pharmaceuticals Stock Is Slumping Today

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

Why Aurinia Pharmaceuticals Stock Is Glowing Green Today

Why Shares of Aurinia Pharmaceuticals Soared This Week

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Why Aurinia Pharmaceuticals Stock Is Sliding Today

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aurinia Pharmaceuticals

AUPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

What is the 52-week range for Aurinia Pharmaceuticals?

How much debt does Aurinia Pharmaceuticals have?

How much cash does Aurinia Pharmaceuticals have on hand?

What is Aurinia Pharmaceuticals’s dividend yield?

Premium Investing Services